Literature DB >> 12126098

Causes of appearance of scintigraphic hot areas on thyroid scintigraphy analyzed with clinical features and comparative ultrasonographic findings.

Masahiro Iwata1, Kanji Kasagi, Hiroto Hatabu, Takashi Misaki, Yasuhiro Iida, Toru Fujita, Junji Konishi.   

Abstract

This study was done retrospectively to analyze the ultrasonographic (US) findings in thyroid scintigraphic hot areas (HA). Three-thousand, eight-hundred and thirty-nine consecutive patients who underwent 99mTc-pertechnetate (n = 3435) or 123I (n = 457) scintigraphy were analyzed. HA were regarded as present when the tracer concentration was greater than the remaining thyroid tissue, or when hemilobar uptake was observed. High-resolution US examinations were performed with a real-time electronic linear scanner with a 7.5 or 10 MHz transducer. One hundred and four (2.7%) were found to be scintigraphic HA (n = 120). US revealed a nodular lesion or well-demarcated thyroid tissue corresponding to the HA in 94 areas (78.4%, Category 1), an ill-defined region with different echogenicity in 13 areas (10.8%, Category 2), and no correlating lesion in 13 areas (10.8%, Category 3). These 104 patients included 43 with adenomatous goiter (59 areas), 33 with adenoma, 11 with Hashimoto's thyroiditis, 5 with primary thyroid cancer, 4 with euthyroid ophthalmic Graves' disease (EOG), 3 with hemilobar atrophy or hypogenesis, 2 with hemilobar agenesis, 2 with hypothyroidism with blocking-type TSH-receptor antibodies (TSHRAb), I with acute suppurative thyroiditis. Among the 59 adenomatous nodules and 33 adenomas, 51 (86.4%) and 32 (97.0%), respectively, belonged to Category 1. A solitary toxic nodule was significantly larger and occurs more often in older patients than in younger patients. On the other hand, all 17 patients with known autoimmune thyroid diseases including Hashimoto's thyroiditis, EOG and hypothyroidism with blocking TSHRAb belonged to Category 2 or 3. Possible underlying mechanisms are 1) hyperfunctioning tumors or nodules, 2) localized functioning thyroid tissue freed from autoimmune destruction, inflammation or tumor invasion, 3) congenital abnormality, 4) clusters of hyperactive follicular cells caused by long-term TSH and/or TSHRAb stimulation, 5) asymmetry, etc. Scintigraphic HA are observed in patients with various thyroid diseases and high-resolution US appears to be helpful clinically for the differential diagnosis of the above mentioned disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126098     DOI: 10.1007/bf03000108

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  5 in total

1.  Papillary thyroid carcinoma presenting as a functioning thyroid nodule: report of 2 rare cases.

Authors:  Liang Hu; Yijun Wu
Journal:  Int J Clin Exp Pathol       Date:  2020-11-01

2.  Hyperfunction thyroid nodules: their risk for becoming or being associated with thyroid cancers.

Authors:  Eun Sun Lee; Ji-Hoon Kim; Dong Gyu Na; Jin Chul Paeng; Hye Sook Min; Seung Hong Choi; Chul Ho Sohn; Ki-Hyun Chang
Journal:  Korean J Radiol       Date:  2013-07-17       Impact factor: 3.500

3.  A solitary hyperfunctioning thyroid nodule harboring thyroid carcinoma: review of the literature.

Authors:  Sasan Mirfakhraee; Dana Mathews; Lan Peng; Stacey Woodruff; Jeffrey M Zigman
Journal:  Thyroid Res       Date:  2013-05-04

4.  A Rare Presentation of Autonomously Functioning Papillary Thyroid Cancer: Malignancy in Marine-Lenhart Syndrome Nodule.

Authors:  Mehmet Uludag; Nurcihan Aygun; Alper Ozel; Feyza Yener Ozturk; Rabia Karasu; Banu Yilmaz Ozguven; Bulent Citgez; Mehmet Mihmanli; Adnan Isgor
Journal:  Case Rep Surg       Date:  2016-03-27

5.  Prevalence of hyperfunctioning thyroid nodules among those in need of fine needle aspiration cytology according to ATA 2015, EU-TIRADS, and ACR-TIRADS.

Authors:  Benjamin Noto; Maria Eveslage; Michaela Pixberg; José Manuel Gonzalez Carvalho; Michael Schäfers; Burkhard Riemann; Peter Kies
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-09       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.